Oral Contraceptive DDI Study

Inclusion Criteria: * Premenopausal females with a body mass index (BMI) between 18 and 32 kg/m2 (inclusive) * Have not received any oral contraceptives during the Screening period or for at least 15 days prior to the first dose of Period 1 Exclusion Criteria: * History of any contraindications to the combined oral contraceptive tablet including thrombosis and the history of any thromboembolic disease, recurrent jaundice, acute or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding, significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or suspected) * Prior exposure to sotagliflozin (LX4211) * History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality * Concurrent conditions that could interfere with safety and/or tolerability measurements * Women who are breastfeeding or are planning to become pregnant during the study * Positive serum pregnancy test * Have taken injectable contraceptives or hormonal intrauterine devices within 12 months prior to the first dose of Period 1 or topical controlled delivery contraceptives (patch) for 3 months prior to the first dose of Period 1